Regularly testing large numbers of people will play a huge role in monitoring transmission of SARS-CoV-2. Quickly detecting and isolating active cases – people who can transmit the virus, whether symptomatic or asymptomatic – is the cornerstone for limiting disease spread. In addition, accurate data on the number of active cases is necessary to inform policy makers (at local, state, and federal levels) as well as individuals what the short-term risk of spread is and how safe it is to do things like return to workplaces, attend school, and see friends and family.
What is SalivaDirect™?
Ramping up testing for effective SARS-CoV-2 surveillance has faced several barriers. One of those is the reliance on nasopharyngeal, NP, swabs. Being tested with these swabs can be uncomfortable, which discourages people from getting tested. NP swabs, also, have to be collected by a trained medical professional, adding a logistical barrier and putting those collecting the sample at risk of exposure. Because SARS-CoV-2 rapidly spread worldwide, it has put immense strain on the supply chains that provide materials for tests, including swabs and test reagents. SalivaDirect™ is our answer to these problems. SalivaDirect™ is a new method for testing people suspected of SARS-CoV-2 infection. While it still relies on a similar molecular process as earlier tests (called RT-qPCR), SalivaDirect™ made it easier to drive down costs and place less stress on the supply chains.
Elevation Diagnostics is designated to use this FDA EUA. Find our designation here: https://www.salivadirect.org/authorized-labs/